<?xml version="1.0" encoding="UTF-8"?>
<ref id="hep41480-bib-0073">
 <label>73</label>
 <mixed-citation publication-type="journal" id="hep41480-cit-0073">
  <string-name>
   <surname>Yurdaydin</surname>
   <given-names>C</given-names>
  </string-name>, 
  <string-name>
   <surname>Keskin</surname>
   <given-names>O</given-names>
  </string-name>, 
  <string-name>
   <surname>Kalkan</surname>
   <given-names>Ç</given-names>
  </string-name>, 
  <string-name>
   <surname>Karakaya</surname>
   <given-names>F</given-names>
  </string-name>, 
  <string-name>
   <surname>Çalişkan</surname>
   <given-names>A</given-names>
  </string-name>, 
  <string-name>
   <surname>Karatayli</surname>
   <given-names>E</given-names>
  </string-name>, et al. 
  <article-title>Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV‐1 study</article-title>. 
  <source xml:lang="en">Hepatology</source>
  <year>2018</year>;
  <volume>67</volume>:
  <fpage>1224</fpage>‐
  <lpage>1236</lpage>.
  <pub-id pub-id-type="pmid">29152762</pub-id>
 </mixed-citation>
</ref>
